The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

  • LOG IN
  • BECOME A MEMBER
  • About
    • Mission & Activities
    • Directors and Officers
    • The Antibody Society’s Committees
      • AIRR Community Committee
      • Communication & Membership Committee
      • Meetings Committee
    • Sponsors & Partners
  • Society meetings
    • Harnessing Cytokines for Cancer Immunotherapy Symposium
    • Biopharmaceutical Informatics Symposium
    • Emerging Cancer Therapies Leveraging Gamma-Delta Effector T cells Symposium
    • Emerging Immunotherapeutics for Ovarian Cancer Symposium
    • AIRR Community Meetings
    • Antibody Engineering & Therapeutics (US) 2023
      • 2022 Antibody Engineering & Therapeutics
      • 2020 Antibody Engineering & Therapeutics
      • 2019 Antibody Engineering & Therapeutics
      • 2018 Antibody Engineering & Therapeutics
      • What is INN a Name?
        • INN issue updates
    • Antibody Engineering & Therapeutics Europe 2023
    • FOCIS Symposia
  • AIRR Community
    • AIRR News
    • AIRR Publications
    • AIRR Meetings
      • AIRR Community Special Event 2023  – Zooming in to the Community II
      • AIRR Community Meeting VI: “Exploring New Frontiers”
      • AIRR Community Meeting V: “Zooming in to the AIRR Community”
      • AIRR Community Meeting V Pre-Meetings
        • AIRR-seq in the Pandemic
        • AIRR-seq Biological Standards and Workflows
      • AIRR Community Special Event: “Response to COVID-19”
      • AIRR Community Meeting IV: “Bridging the Gaps”
      • AIRR Community Meeting III
        • Day 1
        • Day 2
        • Day 3
        • Day 4
      • AIRR Community Meeting II
      • AIRR Community Meeting I
    • AIRR Community Working Groups
      • Biological Resources Working Group
      • Common Repository Working Group
      • Diagnostics Working Group
      • Germline Database Working Group
      • Legal and Ethics Working Group
      • Software Working Group
      • Standards Working Group
    • AIRR Community Sub-committees
      • Communications Sub-committee
      • Executive Sub-committee
      • Inferred Allele Review Committee
      • Meetings Sub-committee
    • AIRR Data Commons
    • AIRR Community Calendar
    • AIRR Community Webinar Series
    • On AIRR – An AIRR Community Podcast
    • AIRR Community Resources
    • AIRR Community Service Prize 2022
  • Members only
    • Login
    • Note to members
    • Member discount codes
    • 2023 Calendar of Events
    • James S. Huston Antibody Science Talent Award
      • 2021 James S. Huston Antibody Science Talent Award Recipient
      • 2020 James S. Huston Antibody Science Talent Award Recipient
      • JSH Award Criteria
    • Science Writing Competition
      • Science Writing Competition Winners
    • Imaging Competition
    • Research Competitions
      • Research Competition Winners
    • Antibodies in early-stage studies
    • Presentations
  • Upcoming meetings
  • Web Resources
    • Society Publications
    • Antibody News
    • Antibody therapeutics approved or in regulatory review in the EU or US
      • Antibody therapeutics product data
    • Antibodies in late-stage clinical studies
    • Research Resources
    • Education Resources
  • Career Center
    • Career Shorts
  • Learning Center
    • Upcoming Webinars
    • Snakebite antivenoms: Global challenges and progress toward recombinant antibody therapeutics
    • Adaptive Immune Receptor Repertoires
    • Antibody Discovery & Development
    • Commercializing Antibody Therapeutics
    • Antibodies to Watch
    • Antibody Validation
  • COVID-19
    • Guide to “Coronavirus in the Crosshairs”
    • COVID-19 Biologics Tracker
    • Meeting Report: The Diagnostic Landscape for COVID-19
You are here: Home / Aldrin Gomes, PhD & James Trimmer, PhD

Aldrin Gomes, PhD & James Trimmer, PhD

Speaker: Dr. Aldrin V. Gomes is currently Professor and Vice-Chair of Teaching and Curriculum in the Department of Neurobiology, Physiology, and Behavior at the University of California, Davis (USA). He has published more than 180 papers in journals, books and conference proceedings, including articles in Circulation, FASEB Journal, Circulation Research, and Molecular and Cellular Proteomics. He is on the editorial board of seven journals and is fellow of the American Heart Association (FAHA) and the cardiovascular section of the American Physiological Society (FCVS). He has written extensively on how to improve the rigor and reproducibility of Western blotting and has collaborated with several companies to improve reagents used for Western Blotting. His research is focused on understanding the molecular mechanisms involved in cardiovascular diseases.

 

 

Speaker: Jim Trimmer is Distinguished Professor of Physiology and Membrane Biology at the University of California School of Medicine, where his research program focuses on the expression, localization and function of neuronal ion channel complexes at the proteomic level, and on generation, validation and use of antibodies in diverse neuroscience research applications. He founded and directs the UC Davis/NIH NeuroMab Facility that generates high-quality, low-cost monoclonal antibodies for neuroscience research. Validation efforts include diverse assays on brain samples including immunohistochemistry, and transparent reporting of the results, enhancing the utility of NeuroMabs across many areas of neuroscience research. As of August 2019, these efforts have resulted in distribution of over 64,000 vials of low-cost antibodies, and over 3,000 research publications citing this facility. His lab’s recent efforts have also included converting these antibodies into recombinant form and generating and characterizing single-chain binders in the form of mAb-derived scFvs and nanobodies, in part for enhanced imaging resolution and tissue penetration versus larger conventional antibodies.

 

Dr. Simon Goodman moderates this webinar series.

 

References from Dr. Gomes:

Gilda JE, Ghosh R, Cheah JX, West TM, Bodine SC, Gomes AV. Western Blotting Inaccuracies with Unverified Antibodies: Need for a Western Blotting Minimal Reporting Standard (WBMRS). PLoS One. 2015 Aug 19;10(8):e0135392. doi: 10.1371/journal.pone.0135392.

Trent A. J. Butler, Jonathan W. Paul, Eng-Cheng Chan, Roger Smith, Jorge M. Tolosa. Misleading Westerns: Common Quantification Mistakes in Western Blot Densitometry and Proposed Corrective Measures Biomed Res Int. 2019; 2019: 5214821.  doi: 10.1155/2019/5214821

Ghosh R, Gilda JE, Gomes AV. The necessity of and strategies for improving confidence in the accuracy of western blots. Expert Rev Proteomics. 2014 Oct;11(5):549-60.  doi: 10.1586/14789450.2014.939635.

Meliopoulos VA, Schultz-Cherry S. Although it’s painful: The importance of stringent antibody validation. PLoS Pathog. 2018 Jan 4;14(1):e1006701. doi: 10.1371/journal.ppat.1006701.

Andrea Degasperi, Marc R. Birtwistle, Natalia Volinsky, Jens Rauch, Walter Kolch, Boris N. Kholodenko. Evaluating Strategies to Normalise Biological Replicates of Western Blot Data PLoS One. 2014; 9(1): e87293. doi: 10.1371/journal.pone.0087293

Moritz CP. Tubulin or Not Tubulin: Heading Toward Total Protein Staining as Loading Control in Western Blots. Proteomics. 2017 Oct;17(20). doi: 10.1002/pmic.201600189.

Hu X, Du S, Yu J, Yang X, Yang C, Zhou D, Wang Q, Qin S, Yan X, He L, Han D, Wan C. Common housekeeping proteins are upregulated in colorectal adenocarcinoma and hepatocellular carcinoma, making the total protein a better “housekeeper”. Oncotarget. 2016 Oct 11;7(41):66679-66688. doi: 10.18632/oncotarget.11439.

 

References from Dr. Trimmer:

Gong B, Murray KD, Trimmer JS. Developing high-quality mouse monoclonal antibodies for neuroscience research – approaches, perspectives and opportunities. N Biotechnol. 2016;33(5 Pt A):551–564. doi: 10.1016/j.nbt.2015.11.007

Manning CF, Bundros AM, Trimmer JS. Benefits and pitfalls of secondary antibodies: why choosing the right secondary is of primary importance. PLoS One. 2012;7(6):e38313. doi: 10.1371/journal.pone.0038313

Taussig MJ, Fonseca C, Trimmer JS. Antibody validation: a view from the mountains. N Biotechnol. 2018;45:1–8. doi: 10.1016/j.nbt.2018.08.002

Lorincz A, Nusser Z. Specificity of immunoreactions: the importance of testing specificity in each method. J Neurosci. 2008;28(37):9083–9086. DOI: 10.1523/JNEUROSCI.2494-08.2008

Goodman SL. The path to VICTORy – a beginner’s guide to success using commercial research antibodies. J Cell Sci. 2018;131(10):jcs216416. Published 2018 May 15. doi: 10.1242/jcs.216416

mabs

mabs

The Official Journal of The Antibody Society

Career Center

Our Career Center is a premier resource to connect highly qualified talent with matching career opportunities. Visit for details on over 800 jobs!

AIRR Community

AIRR Community

The Adaptive Immune Receptor Repertoire Community is a research-driven group organizing around the use of high-throughput sequencing technologies to study antibody/B-cell and T-cell receptor repertoires.

Recent Posts

  • FDA approves Zynyz™ (retifanlimab-dlwr) for Merkel cell carcinoma March 23, 2023
  • Ultralong CDR H3-based knobs: the smallest antibody fragment March 6, 2023
  • TRUST4 is now certified as AIRR-compliant March 1, 2023

Archives

Follow us online

  • Email
  • LinkedIn
  • Twitter
  • YouTube
  • Home
  • Privacy & Terms of Use
  • About
  • Directors and Officers
  • Advisors
  • Sponsors & Partners
  • Mission & Activities
  • Join the Society
  • Membership Levels
  • Members only
  • Login
  • Antibody therapeutics approved or in regulatory review in the EU or US
  • Meeting reports
  • Presentations
  • Contact

©2015 - scicomvisuals